Rangeley Capital, LLC Revance Therapeutics, Inc. Transaction History
Rangeley Capital, LLC
- $111 Billion
- Q4 2024
A detailed history of Rangeley Capital, LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Rangeley Capital, LLC holds 110,000 shares of RVNC stock, worth $282,700. This represents 0.3% of its overall portfolio holdings.
Number of Shares
110,000Holding current value
$282,700% of portfolio
0.3%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding RVNC
# of Institutions
223Shares Held
83.3MCall Options Held
816KPut Options Held
882K-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.63MShares$14.5 Million0.0% of portfolio
-
Oddo Bhf Asset Management Sas Paris, I05.1MShares$13.1 Million0.78% of portfolio
-
Fil LTD Hamilton, D04.19MShares$10.8 Million0.01% of portfolio
-
Alliancebernstein L.P. New York, NY3.5MShares$8.99 Million0.0% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...